Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia.
Immuron continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome due to the virus that causes COVID-19.
Chris Lange The day traders are back at it, chasing stocks on news with very few thoughts about what the fundamentals may be if the good news pans out. In day trading, that just…
Jon C. Ogg 